title: Targeting the NMDA receptor-nitric oxide-cyclic GMP pathway to develop non-dopaminergic antipsychotic medications for schizophrenia.
authors.forename: João Paulo Maia de
authors.initials: JP
authors.lastname: Oliveira
authors.forename: Bruno
authors.initials: B
authors.lastname: Lobão
authors.forename: João Paulo
authors.initials: JP
authors.lastname: Machado-de-Sousa
authors.forename: Glen B
authors.initials: GB
authors.lastname: Baker
authors.forename: Serdar
authors.initials: S
authors.lastname: Dursun
authors.forename: Jaime E C
authors.initials: JE
authors.lastname: Hallak
mesh_terms: D014150:Antipsychotic Agents / Q000627:therapeutic use*; D006152:Cyclic GMP / Q000502:physiology*; D006801:Humans; D009569:Nitric Oxide / Q000502:physiology*; D016194:Receptors, N-Methyl-D-Aspartate / Q000502:physiology*; D012559:Schizophrenia / Q000188:drug therapy* / Q000209:etiology
chemical_list: D014150:Antipsychotic Agents; D016194:Receptors, N-Methyl-D-Aspartate; D009569:Nitric Oxide; D006152:Cyclic GMP